Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Tavist ND Loratadine Tablets Carry Geneva’s Marketing Exclusivity

This article was originally published in The Tan Sheet

Executive Summary

Geneva Pharmaceuticals initially will market the first generic competition to Schering-Plough's OTC Claritin behind pharmacy counters

You may also be interested in...



Novartis Omeprazole Offering, Wellpoint, Prilosec OTC Pressure PPI Prices

Novartis' entrance into the OTC loratadine market in March could set a precedent for the firm to make a similar move with the proton pump inhibitor omeprazole

Novartis Omeprazole Offering, Wellpoint, Prilosec OTC Pressure PPI Prices

Novartis' entrance into the OTC loratadine market in March could set a precedent for the firm to make a similar move with the proton pump inhibitor omeprazole

Novartis Omeprazole Offering, Wellpoint, Prilosec OTC Pressure PPI Prices

Novartis' entrance into the OTC loratadine market in March could set a precedent for the firm to make a similar move with the proton pump inhibitor omeprazole

Related Content

Topics

UsernamePublicRestriction

Register

PS095061

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel